[Hydroxymethyluracil in the correction of adverse effects caused by chemotherapy of malignant neoplasms].
Hydroxymethyluracil (HMU) in a dose of 1.5-3 g/day produces a stimulant effect upon leukopoiesis and granulocytopoiesis in cases of toxic neutropenia caused by chemotherapy. In the same dose range, HMU produces immunostimulant action in patients with immune deficit caused by oncopathology and chemotherapy.
Sakaeva
D D
DD
Pharmacology and Oncology Departments, Bashkir State Medical University, ul. Lenina 3, Ufa, 450000 Russia.
D000276:Adjuvants, Immunologic / Q000494:pharmacology* / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000276:immunology; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology; D010432:Pentoxyl / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; C008055:5-hydroxymethyluracil; D010432:Pentoxyl